Linker Information
General Information of This Linker
| Linker ID |
LIN0CPZVG
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
3-Maleimidopropionic acid linker
|
|||||
| Linker Type |
Uncleavable linker
|
|||||
| Antibody-Linker Relation |
Uncleavable
|
|||||
| Structure |
|
|||||
| Formula |
C7H7NO4
|
|||||
| Isosmiles |
O=C(N1CCC(O)=O)C=CC1=O
|
|||||
| InChI |
InChI=1S/C7H7NO4/c9-5-1-2-6(10)8(5)4-3-7(11)12/h1-2H,3-4H2,(H,11,12)
|
|||||
| InChIKey |
IUTPJBLLJJNPAJ-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
169.136
|
Polar area
|
74.68
|
||
|
Complexity
|
235.2118756
|
xlogp Value
|
-0.6139
|
|||
|
Heavy Count
|
12
|
Rot Bonds
|
3
|
|||
|
Hbond acc
|
3
|
Hbond Donor
|
1
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
US20250025567A1 ExL1A1 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 50% | Positive CLDN6 expression (CLDN6+++/++) | ||
| Method Description |
ExL1A1 was tested in SCID mice that subcutaneously transplanted NUGC33, 3 mg/kg was administeredthrough the tail vein of the tumor-bearing mice.
|
||||
| In Vivo Model | NUGC-3 cells SCID mice model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | The ADC concentration required to produce 10,000 pg/mL TNF-alpha was evaluated. |
100- 1000 nM
|
Positive CLDN6 expression (CLDN6+++/++) | ||
| Method Description |
ExL1A1 was tested in co-culture system consisting of Human peripheral blood mononuclear cells (PBMCs) and NUGC33 cells, with the concentration range of 5.5 uM to 0.97 uM,TNF-a and INF-y productions were measured.
|
||||
| In Vitro Model | Normal; Gastric adenocarcinoma | PBMC cells; NUGC3 cells | .;CVCL_1612 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | The ADC concentration required to produce 10,000 pg/mL INF-Gamma was evaluated. |
10- 100 nM
|
Positive CLDN6 expression (CLDN6+++/++) | ||
| Method Description |
ExL1A1 was tested in co-culture system consisting of Human peripheral blood mononuclear cells (PBMCs) and NUGC33 cells, with the concentration range of 5.5 uM to 0.97 uM,TNF-a and INF-y productions were measured.
|
||||
| In Vitro Model | Normal; Gastric adenocarcinoma | PBMC cells; NUGC3 cells | .;CVCL_1612 | ||
US20250025567A1 ExL7A1 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 50% | Positive CLDN6 expression (CLDN6+++/++) | ||
| Method Description |
ExL7A1 was tested in SCID mice that subcutaneously transplanted NUGC33, 3 mg/kg was administeredthrough the tail vein of the tumor-bearing mice.
|
||||
| In Vivo Model | NUGC-3 cells SCID mice model | ||||
US20250025567A1 ExL1A2 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | The ADC concentration required to produce 10,000 pg/mL TNF-alpha was evaluated. | > 1000 nM | Positive CLDN6 expression (CLDN6+++/++) | ||
| Method Description |
ExL1A2 was tested in co-culture system consisting of Human peripheral blood mononuclear cells (PBMCs) and NUGC33 cells, with the concentration range of 5.5 uM to 0.97 uM,TNF-a and INF-y productions were measured.
|
||||
| In Vitro Model | Normal; Gastric adenocarcinoma | PBMC cells; NUGC3 cells | .;CVCL_1612 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | The ADC concentration required to produce 10,000 pg/mL INF-Gamma was evaluated. |
100- 1000 nM
|
Positive CLDN6 expression (CLDN6+++/++) | ||
| Method Description |
ExL1A2 was tested in co-culture system consisting of Human peripheral blood mononuclear cells (PBMCs) and NUGC33 cells, with the concentration range of 5.5 uM to 0.97 uM,TNF-a and INF-y productions were measured.
|
||||
| In Vitro Model | Normal; Gastric adenocarcinoma | PBMC cells; NUGC3 cells | .;CVCL_1612 | ||